Research any topic before you write.

Find related topics. | Discover entities. | See connections. | Build a topical map.

Lecanemab: History, Community, Culture & Applications

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion or subcutaneous injection. In clinical trials, it demonstrated small or no clinically significant efficacy in Alzheimer's disease. The…

Language: English [EN]
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.
100%
More settings
100% 100% 100% 100% 100%

Lecanemab topic overview

The analysis highlights History, Community, Culture and Applications as prominent areas in the source structure around Lecanemab.

Related topics
49
Source areas
7
Connected nodes
56
Extracted relationships
82
Concept neighborhoods
26
Bridge connections
56

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Overview · 17 topics
History · 12 topics
Research · 8 topics
Society and culture · 5 topics
Medical uses · 3 topics
Pharmacology · 3 topics
Adverse effects · 1 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

AHFS/Drugs.com
Monograph
ATC code
N06DX04 (WHO)
CAS Number
1260393-98-3
ChemSpider
none
DrugBank
DB14580
Formula
C6544H10088N1744O2032S46

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Medical uses

Adverse effects

Pharmacology

History

Society and culture

Research

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

How Lecanemab connects Entity context

The extracted context around Lecanemab shows recurring relationship patterns in the source. For example, Lecanemab → According, After, Alzheimer's, As, At, California Technology Assessment Forum, Clinical, Economic Review, Eisai, However, ICER, Institute, Medicare, This, United States, US Another extracted example is Lecanemab → April, Canada, December, EU, January, July, May, Mexico, October, South Korea, United States. Use these groups to spot repeated connection types before inspecting the individual relationships.

Lecanemab

Top relations

related to Economics · 16
Lecanemab → According, After, Alzheimer's, As, At, California Technology Assessment Forum, Clinical, Economic Review, Eisai, However, ICER, Institute, Medicare, This, United States, US
related to Legal status · 11
Lecanemab → April, Canada, December, EU, January, July, May, Mexico, October, South Korea, United States
related to history · 7
Lecanemab → Biogen, Drug Administration, FDA, III, In July, In September, US Food
related to Reception · 6
Lecanemab → Do Not Use, FDA, Group, In October, It, Public Citizen's Health Research
related to Research · 5
Lecanemab → Alzheimer's, BioArctic, Biogen, Eisai, It
Legal status · 4
Lecanemab → CA: ℞-only / Schedule D, EU: Rx-only, Rx-only, US: ℞-only
has effect · 3
Lecanemab → ARIA, Compared, However
is a · 2
Lecanemab → amyloid beta-directed antibody, humanized monoclonal antibody consisting of a humanized version of a mouse antibody
related to Efficacy · 2
Lecanemab → Alzheimer's, Cochrane
AHFS/Drugs.com · 1
Lecanemab → Monograph

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

alzheimer's disease treatment amyloid clinical people fda mild eisai may approval participants small leqembi dementia placebo antibody cognitive 2023 2025

Lecanemab relationships Subject–Predicate–Object triples

TTTA extracted 82 structured relationships around Lecanemab. Examples in this analysis include Lecanemab → AHFS/Drugs.com → Monograph and Lecanemab → ATC code → N06DX04 (WHO). The table shows each extracted connection, where it came from and its confidence.

SubjectPredicateObjectConfidenceSrc
LecanemabAHFS/Drugs.comMonograph1.00infobox
LecanemabATC codeN06DX04 (WHO)1.00infobox
LecanemabCAS Number1260393-98-31.00infobox
LecanemabChemSpidernone1.00infobox
LecanemabDrugBankDB145801.00infobox
LecanemabFormulaC6544H10088N1744O2032S461.00infobox
LecanemabKEGGD116781.00infobox
LecanemabLegal statusCA: ℞-only / Schedule D1.00infobox
LecanemabLegal statusUS: ℞-only1.00infobox
LecanemabLegal statusEU: Rx-only1.00infobox
LecanemabLegal statusRx-only1.00infobox
LecanemabLicense dataUS DailyMed: Lecanemab1.00infobox
LecanemabMedlinePlusa6230041.00infobox
LecanemabMolar mass147181.62 g·mol−11.00infobox
LecanemabOther namesBAN2401, lecanemab-irmb1.00infobox
LecanemabRoutes of administrationIntravenous, subcutaneous1.00infobox
LecanemabSourceHumanized1.00infobox
LecanemabTargetAmyloid beta1.00infobox
LecanemabTrade namesLeqembi1.00infobox
LecanemabTypeWhole antibody1.00infobox
LecanemabUNII12PYH0FTU91.00infobox
Lecanemabis aamyloid beta-directed antibody0.90text
Lecanemabis ahumanized monoclonal antibody consisting of a humanized version of a mouse antibody0.90text

Related concept clusters Concept neighborhoods

The concept neighborhoods around Lecanemab bring nearby vocabulary together. In this analysis, examples include Alzheimer's, Disease and Approval. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

  • Lecanemab
    • Alzheimer's
    • Disease
    • Approval
    • Fda
    • July
    • Use
    • Treatment
    • Amyloid
    • Clinical
    • Antibody
    • Medical
    • Accelerated
  • lecanemab
    • Alzheimer's
    • Disease
    • Approval
    • Fda
    • July
    • Use
    • Treatment
    • Amyloid
    • Clinical
    • Antibody
    • Medical
    • Accelerated
  • alzheimer's disease
    • Disease
    • Treatment
    • Mild
    • Impairment
    • Cognitive
    • People
    • Beta
    • Dementia
    • Lecanemab
    • Participants
    • Amyloid
    • Antibody
  • alzheimer's disease assessment scale cognitive subscale
    • Impairment
    • Disease
    • Mild
    • Dementia
    • Treatment
    • Participants
    • Cognitive
    • People
    • Significant
    • Beta
    • Lecanemab
    • Leqembi
  • alzheimer's disease cooperative study
    • Disease
    • Treatment
    • Mild
    • Impairment
    • Cognitive
    • People
    • Beta
    • Dementia
    • Lecanemab
    • Participants
    • Amyloid
    • Antibody
  • amyloid beta
    • Beta
    • Dementia
    • Impairment
    • Cognitive
    • Antibody
    • Mild
    • Participants
    • Treatment
    • Disease
    • Effects
    • Brain
    • Subcutaneous
  • clinical dementia rating
    • Impairment
    • Mild
    • Leqembi
    • Disease
    • Biogen
    • Participants
    • Treatment
    • Efficacy
    • People
    • Small
    • Effects
    • Subcutaneous
  • monoclonal antibody
    • Amyloid
    • Beta
    • Leqembi
    • Mild
    • Alzheimer's
    • Disease
    • Effects
    • Subcutaneous
    • Efficacy
    • European
    • Medical
    • Dementia

Connections between topic areas Semantic bridges

For Lecanemab, one of the stronger structural bridges in this analysis connects Lecanemab with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3
LecanemabOverview · splits 39 ⟂ 18
LecanemabHistory · splits 44 ⟂ 13
LecanemabResearch · splits 48 ⟂ 9
LecanemabSociety and culture · splits 51 ⟂ 6
LecanemabMedical uses · splits 53 ⟂ 4
LecanemabPharmacology · splits 53 ⟂ 4

Map overview Semantic statistics

Lecanemab

Nodes57
Edges56
Triples82
Avg. degree1.96
Density0.035088
Components1

Source & methodology

TTTA analyzes the structure around Lecanemab to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Community, Culture & Applications, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Lecanemab · EN edition · Analysis: TopicsToTalkAbout

For writers, content strategists, SEOs, marketers and creators — from quick topic research to advanced semantic analysis.